Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

How Incepta Is Shaping Bangladesh's Vaccines Future

Executive Summary

Bangladesh's Incepta group has launched its vaccine bulk manufacturing facility – a move that could have a significant impact on cost dynamics in a country that imports over 90 million doses of vaccines each year under its infant immunization plan. Incepta's chair Abdul Muktadir tells Scrip why this facility can make a difference and also outlines plans on the firm's tetravalent HPV vaccine.

Advertisement

Related Content

Incepta’s Vaccine Ambitions Bridled By Bangladesh Regulatory Gap

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel